Eicosapentaenoic Acid for Cardiovascular Events Reduction- Systematic Review and Network Meta-Analysis of Randomized...

Area of Science:

• Cardiology
• Nutritional Science
• Clinical Trials

Background:

• Previous randomized clinical trials (RCTs) on omega-3 fatty acids for cardiovascular events yielded mixed results.
• A debate exists regarding the inertness of placebo used in omega-3 supplementation trials.
• This study performed a network meta-analysis to investigate omega-3s versus various placebo oils.

Purpose of the Study:

• To compare cardiovascular outcomes of omega-3 fatty acid supplementation against diverse placebo controls.
• To evaluate the impact of different omega-3 formulations (EPA, DHA, EPA+DHA) and placebo types on cardiovascular events.

Main Methods:

• A network meta-analysis of 17 randomized clinical trials (RCTs) was conducted.
• Data from 141,009 patients were analyzed, comparing eicosapentaenoic acid (EPA), EPA+docosahexaenoic acid (DHA), and various placebo oils (mineral, corn, olive) or controls.
• Searches were performed in MEDLINE and EMBASE up to May 2021.

Main Results:

• Eicosapentaenoic acid (EPA) supplementation significantly lowered rates of cardiovascular death, myocardial infarction, and stroke compared to mineral oil placebo.
• EPA also reduced coronary revascularization rates compared to other placebo oils and EPA+DHA.
• Combined EPA+DHA showed a reduced risk of cardiovascular death compared to controls.

Conclusions:

• EPA supplementation demonstrates cardiovascular benefits primarily when compared to mineral oil, not other placebos or controls.
• While EPA reduces revascularization, its benefit over standard care requires further investigation.
• Combined EPA+DHA offers a potential reduction in cardiovascular death risk versus controls.